Hilltop National Bank Takes $168,000 Position in Cencora, Inc. $COR

Hilltop National Bank acquired a new position in Cencora, Inc. (NYSE:COR) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 560 shares of the company’s stock, valued at approximately $168,000.

Several other large investors have also recently bought and sold shares of the company. Cornerstone Planning Group LLC raised its position in shares of Cencora by 106.7% during the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock worth $26,000 after acquiring an additional 48 shares during the last quarter. Hoey Investments Inc. acquired a new stake in Cencora in the first quarter worth about $28,000. Costello Asset Management INC bought a new stake in Cencora during the 1st quarter worth about $28,000. University of Texas Texas AM Investment Management Co. acquired a new position in Cencora during the 1st quarter valued at about $39,000. Finally, Golden State Wealth Management LLC lifted its position in Cencora by 157.6% during the 1st quarter. Golden State Wealth Management LLC now owns 170 shares of the company’s stock valued at $47,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on COR shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Cencora in a research report on Saturday, September 27th. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Jefferies Financial Group increased their price target on Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, June 30th. Finally, Wells Fargo & Company raised their price target on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $311.25.

Cencora Trading Down 2.0%

Shares of NYSE COR opened at $302.54 on Friday. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $315.23. The stock has a market cap of $58.66 billion, a price-to-earnings ratio of 31.13, a P/E/G ratio of 1.41 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The company’s fifty day moving average is $294.68 and its 200-day moving average is $290.25.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.34 EPS. Equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were given a $0.55 dividend. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is currently 22.63%.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the sale, the chief executive officer directly owned 39,274 shares of the company’s stock, valued at $11,389,460. This represents a 11.49% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,993 shares of company stock valued at $16,292,923. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.